Oppenheimer Raises Price Target on Medtronic (MDT) to $94 Following EPS Beat
- Dow, S&P hit highs; Trump comment hammers drug stocks
- Unusual 11 Mid-Day Movers 12/7: (ANTH) (EMKR) (PLAY) Higher; (SIGM) (OHAI) (FTK) Lower
- Abbott (ABT) Files Complaint to Terminate Alere (ALR) Acquisition
- Western Digital (WDC) Raises Q2 Outlook
- Biotech, Pharma Stocks Weaker Amid Trump Comments on Lower Drug Prices
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Oppenheimer reiterated an Outperform rating on Medtronic, Inc. (NYSE: MDT), and raised the price target to $94.00 (from $90.00), following the company's 1Q earnings report. MDT reported a $0.02 EPS beat, driven by a slightly lower interest expense and tax rate.
Analyst Steven Lichtman commented, "MDT delivered an in-line F1Q operationally with EPS coming in $0.02 ahead on slightly lower interest expense and tax rate. The underlying story remained the same as new product launches, emerging market expansion and hospital service offerings drove ~5%/15% constant currency constant week (CCCW) sales/EPS growth in F1Q. MDT reiterated FY17 guidance, including 5-6% CCCW sales growth and EPS of $4.60-$4.70 (12-16% CCCW). Covidien synergies are on target, and free cash flow is on track to accelerate to $6.5-7.0B in FY17. We continue to see cash flow flexibility providing upside opportunities ahead in the form of accelerated buybacks, solid dividend growth and tuck-in M&A (including the recent Heartware acquisition). MDT’s scale is another key positive in today's environment."
Shares of Medtronic, Inc. closed at $85.39 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wedbush Raises Price Target on Francesca's (FRAN) Following 3Q Report
- Newell Brands (NWL): Cutting PT - Jefferies
- Credit Suisse Downgrades NetApp (NTAP) to Underperform
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Related EntitiesEarnings, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!